
What is claimed is:

1. A compound of Formula (I), a pharmaceutically acceptable salt, a tautomer, a stereoisomer or a geometric isomer thereof,



(I)

wherein,

ring A is selected from the group consisting of C_{3-6} cycloalkyl, phenyl and 5 to 10-membered heteroaryl;

n is selected from 0, 1, 2 or 3;

R_1 is each independently selected from the group consisting of halo, OH, NH_2, CN, C_{1-3} alkyl, C_{1-3} heteroalkyl and phenyl, wherein the C_{1-3} alkyl, C_{1-3} heteroalkyl or phenyl is each optionally substituted with 1, 2 or 3 Rs;

R_2 and R_3 are each independently selected from the group consisting of H, halo, OH, NH_2, CN, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl-$(CH_2)_{1-3}$- and phenyl-$(CH_2)_{1-3}$-, wherein the C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl-$(CH_2)_{1-3}$- or phenyl-$(CH_2)_{1-3}$- is each optionally substituted with 1, 2 or 3 Rs; or

R_2 and R_3 together with the carbon atom to which they are attached form a 3 to 6-membered ring;

R_4 is selected from the group consisting of C_{1-6} alkyl and C_{3-6} cycloalkyl-$(CH_2)_{1-3}$-, wherein the C_{1-6} alkyl or C_{3-6} cycloalkyl-$(CH_2)_{1-3}$- is each optionally substituted with 1, 2 or 3 Rs;

R_5 is selected from the group consisting of H and C_{1-3} alkyl optionally substituted with 1, 2 or 3 Rs;


each R is independently selected from the group consisting of F, Cl, Br, I, OH, Me, NH_2, $NH(CH_3)$ and $N(CH_3)_2$;

wherein the prefix “hetero” in the C_{1-3} heteroalkyl, C_{1-6} heteroalkyl and 5 to 10-membered heteroaryl is each independently selected from the group consisting of -O-, -S-, -NH- and N; and in any one of the above cases, the number of the heteroatom or the group containing the heteroatom is independently selected from 1, 2 or 3.

2. The compound according to claim 1, wherein n is selected from 0, 1 or 2.

3. The compound according to claim 1, wherein R_1 is each independently selected from the group consisting of halo, OH, NH_2, CN, C_{1-3} alkyl, C_{1-3} alkoxy and phenyl, wherein the C_{1-3} alkyl, C_{1-3} alkoxy or phenyl is each optionally substituted with 1, 2 or 3 Rs.










4. The compound according to any one of claims 1 to 3, wherein R_1 is each independently selected from the group consisting of halo, OH, NH_2, CN, C_{1-3} alkoxy, phenyl and C_{1-3} alkyl optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br and I.


5. The compound according to claim 1, wherein R_1 is each independently selected from the group consisting of F, Cl, Br, I, OH, NH_2, CN, Me, CF_3,  and .


6. The compound according to any one of claims 1 to 5, wherein ring A is selected from the group consisting of cyclopropyl, phenyl, 5-membered heteroaryl, 6-membered heteroaryl, and 9-membered heteroaryl.














7. The compound according to claim 1, wherein ring A is selected from the group consisting of cyclopropyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, 1,3,4-oxadiazolyl, thiazolyl, isothiazolyl, thienyl, pyrazolyl, imidazolyl and 1H-indazolyl.






















8. The compound according to claim 7, wherein ring A is selected from phenyl.


9. The compound according to claim 1, wherein a structural unit  in the compound of Formula (I) is selected from the group consisting of , , , , , , , ,



and .

10. The compound according to claim 1, wherein a structural unit  in the compound of Formula (I) is selected from the group consisting of , , , , , , , , , , , ,  and .



11. The compound according to claim 1, wherein a structural unit  in the compound of Formula (I) is selected from the group consisting of , , , , , , , , , , , , , , , , , , , , , , , , , ,





12. The compound according to claim 1, wherein R_2 and R_3 are each independently selected from the group consisting of H, halo, OH, NH_2, CN, C_{1-6} alkyl, C_{1-3} alkoxy, C_{1-3} alkyl-O-C_{1-3} alkyl-, C_{3-6} cycloalkyl-CH_2- and phenyl-CH_2-, wherein the C_{1-6} alkyl, C_{1-3} alkoxy, C_{1-3} alkyl-O-C_{1-3} alkyl-, C_{3-6} cycloalkyl-CH_2- or phenyl-CH_2- is each optionally substituted with 1, 2 or 3 Rs; or R_2 and R_3 together with the carbon atom to which they are attached form a 3 to 6-membered cycloalkyl.

13. The compound according to any one of claims 1 to 12, wherein R_3 is H, and R_2 is selected from the group consisting of H, C_{1-6} alkyl, C_{1-3} alkoxy, C_{1-3} alkyl-O-C_{1-3} alkyl-, C_{3-6} cycloalkyl-CH_2- and phenyl-CH_2-, wherein the C_{1-6} alkyl, C_{1-3} alkoxy, C_{1-3} alkyl-O-C_{1-3} alkyl-, C_{3-6} cycloalkyl-CH_2- or phenyl-CH_2- is each optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, I and hydroxyl.

14. The compound according to claim 13, wherein R_3 is H, and R_2 is selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl-CH_2- and phenyl-CH_2-.

15. The compound according to claim 1, wherein R_3 is H, and R_2 is selected from the group consisting of H, Me,  and .

16. The compound according to any one of claims 1 to 15, wherein R_4 is selected from the group consisting of C_{1-6} alkyl and C_{3-6} cycloalkyl-CH_2-.

17. The compound according to claim 1, wherein R_4 is selected from the group consisting of  and .

18. The compound according to any one of claims 1 to 17, wherein R_5 is selected from the group consisting of H and C_{1-3} alkyl.


19. The compound according to claim 1, wherein R_5 is selected from the group

consisting of H, Me and Et.


20. The compound according to claim 1, wherein each R is independently selected from the group consisting of F, Cl, Br, I, OH, Me and NH_2.

21. The compound according to claim 20, wherein each R is independently selected from the group consisting of F and OH.


22. The compound according to claim 1, wherein the compound of Formula (I) is selected from the group consisting of a compound of Formula (III), a compound of Formula (IV), a compound of Formula (V), a compound of Formula (VI), a compound of Formula (I-a), a compound of Formula (I-b), a compound of Formula (II-a), a compound of Formula (II-b), a compound of Formula (III-a), a compound of Formula (III-b), a compound of Formula (IV-a), a compound of Formula (IV-b), a compound of Formula (VI-a) and a compound of Formula (VI-b),




(III)




(IV)




(V)




(VI)




(I-a)




(I-b)




(II-a)




(II-b)




(III-a)




(III-b)




(IV-a)



(IV-b)



(VI-a)




(VI-b)

,


wherein, ring C is selected from the group consisting of cyclopropyl, 5-membered heteroaryl and 6-membered heteroaryl.

23. The compound according to claim 1, wherein the compound of Formula (I) is selected from a compound of Formula (II)




(II)

24. The compound according to claim 1, wherein the compound of Formula (I) is selected from the group consisting of a compound of Formula (V-a) or a compound of Formula (V-b),







(V-a)

























(V-b)


.























25. The compound according to claim 22, wherein the structural unit  in the Formula (IV-a), Formula (IV-b), Formula (VI-a) or Formula (VI-b) is selected from the group consisting of ,  and .

26. The compound according to claim 1, wherein the compound of Formula (I) is selected from the group consisting of
















































and ,


or a pharmaceutically acceptable salt, a tautomer, a stereoisomer or a geometric isomer



















thereof.




27. The compound according to claim 1, wherein the compound of Formula (I) is selected from the group consisting of

















































































and

,




or a pharmaceutically acceptable salt thereof.

28. A pharmaceutical composition, comprising the compound according to claim 1, or a pharmaceutically acceptable salt, a tautomer, a stereoisomer or a geometric isomer thereof, and a pharmaceutically acceptable carrier, excipient or adjuvant.

29. Use of the compound according to claim 1, or a pharmaceutically acceptable salt, a tautomer, a stereoisomer or a geometric isomer thereof in the preparation of a medicament for alleviating or causing the regression of multiple myeloma.

30. The compound according to claim 1, wherein R_2 and R_3 are each independently selected from the group consisting of H, Me, ,



, ,  and ; or the structural unit 

is .